Every 8-K that Rapport Therapeutics, Inc. (RAPP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RAPP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RAPP filings page.
Rapport Therapeutics reported second quarter 2026 results and detailed progress across its precision neuroscience pipeline. The company recorded a net loss of $56.6 million, driven mainly by higher R&D expenses of $51.4 million and SG&A expenses of $9.4 million as clinical programs expanded.
Cash, cash equivalents and short-term investments totaled $436.1 million as of June 30, 2026, which the company expects will fund operations into the second half of 2029. Net cash used in operating activities was $41.5 million in the quarter.
Pivotal development of lead asset RAP-219 advanced, with Phase 3 FOCUS 1 and FOCUS 2 trials in focal onset seizures enrolling and an open-label safety study underway. Follow-up Phase 2a data showed median reductions of 80%–68% in long episodes and 90%–59% in clinical seizures. The company also highlighted a Phase 2 bipolar mania trial with topline data expected in October 2026, preparation for a Phase 3 trial in primary generalized tonic-clonic seizures in 2027, a long-acting injectable formulation moving toward Phase 1 in 2027, and continued IND-enabling work on RAP-641 for chronic pain and migraine.
Rapport Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on board elections and auditor ratification. As of the April 14, 2026 record date, 47,807,623 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class II directors to serve until the 2029 annual meeting: James Healy, M.D., Ph.D. (41,762,713 votes for and 587,163 withheld), Robert J. Perez (37,592,089 for and 4,757,787 withheld), and Raymond Sanchez, M.D. (41,754,131 for and 595,745 withheld), each with 1,983,035 broker non-votes. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 44,255,547 votes for, 57,445 against, and 19,919 abstentions.
Rapport Therapeutics reported first quarter 2026 results and highlighted major progress for its lead candidate RAP-219. Collaboration revenue was $20.0 million, driven by a new license agreement with Tenacia Biotechnology, while net loss narrowed to $19.9 million from $24.1 million a year earlier.
R&D expenses rose to $32.7 million and G&A to $11.5 million as the pipeline expanded. The company ended the quarter with $476.8 million in cash, cash equivalents and short-term investments, which it expects will fund operations into the second half of 2029.
Phase 2a follow-up data in focal onset seizures showed sustained effects, including a 90% median reduction in clinical seizures over baseline in weeks 9–12. A Phase 3 program in focal onset seizures is on track to start in the second quarter of 2026, and Phase 2 bipolar mania topline data are now expected in the fourth quarter of 2026, earlier than prior guidance.
Rapport Therapeutics reported follow-up data from its Phase 2a trial of RAP-219 in drug‑resistant focal onset seizures, showing sustained efficacy after dosing stopped. In weeks 9‑12, patients saw an 80% median reduction in long episodes and 90% median reduction in clinical seizures versus baseline, and in weeks 13‑16, reductions were 68% and 59%, respectively. Over the full 16‑week treatment plus follow‑up period, median reductions were 69% for long episodes and 68% for clinical seizures, with seizure freedom in 12% of patients.
RAP‑219 is now estimated to have an approximately 22‑day half‑life, with receptor occupancy above 60% throughout follow‑up, and was generally well tolerated, including only mild treatment‑related adverse events in the follow‑up period. Rapport plans two pivotal Phase 3 trials in focal onset seizures starting in the second quarter of 2026, a Phase 3 trial in primary generalized tonic‑clonic seizures in the first half of 2027, and a Phase 2 trial in bipolar mania with topline results expected in the first half of 2027. The company is also advancing a long‑acting injectable formulation and other neurology programs, supported by a cash balance of $490.5 million as of December 31, 2025 and an expected cash runway into the second half of 2029.
Rapport Therapeutics reported larger losses for the fourth quarter and full year 2025 as it ramped investment in its precision neuroscience pipeline. Quarterly net loss was $33.8 million versus $20.0 million a year earlier, and full-year net loss rose to $111.5 million from $78.3 million, driven mainly by higher R&D spending.
R&D expenses reached $94.8 million in 2025, up from $60.9 million, while G&A expenses increased to $30.3 million from $22.1 million. The company ended 2025 with $490.5 million in cash, cash equivalents, and short-term investments and expects this to fund operations into the second half of 2029.
Lead candidate RAP‑219 showed strong Phase 2a results in focal onset seizures, with a 77.8% median seizure reduction, 72% of patients achieving at least 50% reduction, and 24% achieving seizure freedom over eight weeks. Rapport plans to start a Phase 3 program in focal onset seizures in the second quarter of 2026 and expand into primary generalized tonic‑clonic seizures with a Phase 3 trial in 2027.
The company also advanced a Phase 2 trial in bipolar mania, long-acting injectable development, and an α6β4 chronic pain program. A new collaboration with Tenacia Biotechnology grants Tenacia rights to RAP‑219 in Greater China, with Rapport eligible for a $20 million upfront payment, up to $308 million in potential milestones and other payments, and tiered royalties.
Rapport Therapeutics, Inc. filed a prospectus supplement to its effective shelf registration statement to register the offer and sale of up to $110,000,000 of common stock through an at-the-market offering program. The shares may be sold from time to time through or to Leerink Partners LLC and Cantor Fitzgerald & Co., acting as sales agents under an existing Sales Agreement dated July 1, 2025. As of the date of this report, no sales of common stock have been made under the Sales Agreement. The company also filed the related legal opinion of Goodwin Procter LLP as an exhibit.
Rapport Therapeutics, Inc. filed a current report describing new investor communications. On January 7, 2026, the company issued a press release titled “Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline,” which is furnished as an exhibit.
On the same date, Rapport updated its corporate presentation for use with investors, analysts and others, and made it available on the Investors section of its website. The updated presentation is also attached as an exhibit to this report.
Rapport Therapeutics (RAPP) furnished an update on its financial results and business highlights for the quarter ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act. RAPP’s common stock trades on The Nasdaq Global Market.
Rapport Therapeutics, Inc. (RAPP) disclosed a marketed offering of common stock to be sold by the company, with all shares in the offering sold by Rapport. The company states the offering is expected to close on or about September 11, 2025, subject to customary closing conditions.
The filing references a previously filed S-3 (file no. 333-288444) declared effective on July 9, 2025, and a final prospectus supplement dated September 9, 2025 filed on September 10, 2025. An underwriting agreement dated September 9, 2025 names Goldman Sachs, Jefferies, TD Securities (USA) and Stifel as bookrunners. The filing also notes legal opinion and consent from Goodwin Procter LLP and includes Inline XBRL cover page data.
Rapport Therapeutics, Inc. filed an 8-K stating that, effective September 8, 2025, it terminated the sales agreement prospectus tied to its Form S-3 registration statement (File No. 333-288444) for common stock sales through Leerink Partners LLC and Cantor Fitzgerald & Co.
The underlying Sales Agreement dated July 1, 2025 remains in full force and effect, but the company cannot sell common stock under it unless a new prospectus, prospectus supplement or new registration statement is filed. As of September 8, 2025, the company had not issued or sold any shares under this Sales Agreement.
Rapport Therapeutics reported topline Phase 2a efficacy for RAP-219 in drug-resistant focal onset seizures showing strong short-term clinical responses. In the 8-week treatment period, 85.2% of patients achieved a ≥30% reduction in lifetime events (LEs) from baseline, 72.0% achieved a ≥50% reduction in clinical seizures, and 24% achieved seizure freedom; all responder endpoints reported p<0.0001. Median reductions were assessed versus appropriate null hypotheses using Wilcoxon signed rank tests and exact binomial tests for responder rates.
The company said RAP-219 was generally well-tolerated with mostly mild treatment-emergent adverse events and a low discontinuation rate. Rapport noted ongoing 8-week follow-up, plans for Phase 3 trials in focal onset seizures, a Phase 2 bipolar mania study, exploration of a long-acting injectable formulation, and expects initial pharmacokinetic results in 2027. A press release and corporate presentation were furnished and a webcast presentation will be posted on the company website.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) filed a Form 8-K to report the voting results of its 2025 Annual Meeting of Stockholders held on June 17 2025. Of the 36,497,555 shares outstanding on the record date, a quorum was present.
Proposal 1 – Election of three Class I directors (terms expiring 2028)
- Reid Huber, Ph.D.: 31,146,580 for, 776,312 withheld, 1,016,695 broker non-votes
- John Maraganore, Ph.D.: 31,222,571 for, 700,321 withheld, 1,016,695 broker non-votes
- Wendy B. Young, Ph.D.: 31,783,990 for, 138,902 withheld, 1,016,695 broker non-votes
All nominees received a clear majority of votes cast and were duly elected.
Proposal 2 – Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2025
- 32,804,657 for, 112,489 against, 22,441 abstain
The appointment of PwC was ratified by 99.4 % of votes cast.
No additional matters were brought to a vote. The filing is routine in nature, dealing solely with corporate governance decisions without disclosing any operational or financial performance data.